Close menu




January 14th, 2020 | 10:54 CET

Ballard Power, dynaCERT, Tesla - the strength of innovations and solutions

  • Innovations
Photo credits: pixabay.com

On the capital market investors find an infinite variety of possibilities to invest their money. There are listed companies that have a history and are valued on the basis of compliance with prospects and fundamentals. And then there are innovative companies that attract capital regardless of all valuation parameters because they have a product that solves problems and arouses desires. If the product is also scalable, then the potential of the shares is often exorbitant, depending on the market size.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA26780A1084 , CA0585861085 , US88160R1014

Table of contents:


    Ballard Power with hydrogen

    The Canadian fuel cell manufacturer Ballard Power has experienced a veritable price rally over the past 12 months. During this period, the company's share price rose from below EUR 2.80 to over EUR 9.50. The shareholders were able to achieve a return of over 230%.

    The market capitalization is now quoted at over 2 billion EUR. The topic of hydrogen in modern mobility is gaining more and more interest and based on that investors are looking for investment opportunities that are active in this field with scalable products.

    dynaCERT makes diesel greener

    Also located in Canada is the innovative company dynaCERT. After more than 15 years of research and development, the experts for hydrogen technologies were able to bring a device to series production readiness with which diesel engines can be retrofitted. The advantage of the technology is that the consumption of diesel can be reduced by up to 18% and, in addition, emissions of NOx, carbon dioxide and particulate matter are also significantly reduced.

    As currently circa one billion diesel engines are in operation and the use of dynaCERT's HydraGEN technology not only offers high savings in fuel consumption but also protects the environment, the share price could increase from below EUR 0.17 to over EUR 0.72 in the past 12 months. With a market value of EUR 230 million, the company is still a lightweight compared to Ballard Power.

    Tesla and the battery car

    Tesla from the USA is a prime example of a new trend. The manufacturer of battery cars has been the focus of reporting for over a decade. The founder at the top of the company is Elon Musk. He is driving Tesla's innovations forward and his announcements are causing euphoria and imagination on the capital market. It's hard to imagine that Tesla today would have a valuation of over EUR 81 billion if Tesla had been led by an employed CEO over the past ten years.

    Musk is there with passion and emotion, and this is the only way to keep the company continuously alive with new cash injections. The share price increased by over 60% from EUR 290.00 to EUR 475.00 in the comparison period. Ten years ago, Tesla shares changed hands at less than EUR 15.00, which clearly shows how enormous the potential of innovations and trends can be.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on December 9th, 2025 | 07:05 CET

    Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology

    • Biotechnology
    • Pharma
    • Biotech
    • Cancer
    • Innovations

    Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.

    Read

    Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET

    Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.

    Read

    Commented by André Will-Laudien on November 25th, 2025 | 07:50 CET

    AI mania, critical metals, and gold! Keep an eye on blockbuster stocks such as BASF, RZOLV Technologies, and Barrick Mining

    • Mining
    • CriticalMetals
    • Gold
    • chemicals
    • Innovations
    • Technology

    The breathtaking advances in high-tech and artificial intelligence require a strong focus on raw materials companies in order to provide the necessary strategic metals in a timely manner. Securing supply chains is all the more important for Western industries because the availability of raw materials is subject to geopolitical skirmishes between some countries that still control the decisive masses in critical areas. This is particularly true for China and Russia. If nothing arrives in the West, production lines come to a standstill or company managers have to accept expensive detours. For equity investors, it is always worthwhile to take a clear look at the key levers. However, the focus is also on the manufacturing processes.

    Read